Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
Suresh S. Ramalingam, Jeffrey Crawford, Alex Y. Chang et al. · Annals of Oncology · 2013
Cited by 57 works. doi:10.1093/annonc/mdt371 Open-access PDF
Authors
- Suresh S. Ramalingam
- Jeffrey Crawford
- Alex Y. Chang
- C. Manegold
- Roman Perez-Soler
- Jean-Yves Douillard
- N. Thatcher
- Fabrice Barlési
- Taofeek Kunle Owonikoko
- Y. Wang
- Philippe Pultar
- Jing Hai Zhu
- Rajesh K. Malik
- Giuseppe Giaccone
- Stephen A. Della‐Fiorentina
- Stephen D. Begbie
- Ross R. Jennens
- Joshua Dass
- Kenneth B. Pittman
References
- Cancer Statistics, 2010
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
- Lung Cancer
- American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- Non-Small Cell Lung Cancer
- 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
- Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study